Kornimate/medical-research-clean huggingface dataset:
early treatment of arni on myocardial remodeling and progress

Conditions: Myocardial Infarction

Summary: myocardial remodeling following myocardial infarction (mi) is an important prognostic factor for heart function and adverse cardiovascular events, especially are intimately linked with heart failure. mi often causes deleterious changes in ventricular size, shape, and function. this adverse remodeling and progress is mediated by neurohormonal and hemodynamic alterations. the angiotensin receptor neprilysin inhibitor (arni) sacubitril/valsartan was shown to be superior to an ace inhibitor in patients with heart failure with reduced ejection fraction (hf-ref), reduce the risk of both death (from cardiovascular and all-causes) and heart failure hospitalization, may be a new approach to the treatment of heart failure. however, the impact of early treatment of arni on myocardial remodeling and progress, and aerobic exercise capacity in patients with prior mi has yet to be assessed. the aim of this study is to evaluate the efficacy and the safety of early treatment of arni on myocardial remodeling and progress, and aerobic exercise capacity in patients following mi.

myocardial remodeling following myocardial infarction (mi) is an important prognostic factor for heart function and adverse cardiovascular events. the angiotensin receptor neprilysin inhibitor (arni) sacubitril/valsartan was shown to reduce the risk of both death (from cardiovascular and all-causes) and heart failure hospitalization. however, whether early treatment of arni following post-mi could alter myocardial remodeling or aerobic exercise capacity has yet to be assessed. the patients with mi within one month were enrolled in the treatment of arni group or acei group. the study proposes to perform serial cardiopulmonary exercise tests (cpet) to prospectively measure changes in aerobic exercise capacity in patients with prior myocardial infarction (mi), echocardiographic measures of lv end-diastolic/ systolic volumes, lv ejection fraction (lvef), bnp and protein plasma levels, symptomatic heart failure, and life quality.

Eligibility criteria:
inclusion criteria: 1. acute myocardial infarction (ami) within 1 months prior to recruitment; 2. aged 18 years or over and under 80 years; 3. randomized patients will have been hemodynamically stable, sbp ≥100mmhg, no symptomatic hypotension; 4. nyha class ⅱ-ⅳ, hfref or hfpef; 5. elevated nt-probnp or bnp at the time of screening; 6. peak vo2/kg\<16 ml/kg/min by cpet exclusion criteria: 1. inability to complete a cpet; 2. symptomatic hypotension and/or systolic blood pressure \<100mmhg; 3. egfr \ 5.2mmol/l; 4. history of hypersensitivity or allergy to ace-inhibitors/arb 5. history of angioedema; 6. pregnancy, planning pregnancy, or breast feeding; 7. life-threatening diseases with limited life expectancy \<1 year
study of the influence of vaccination in hiv viral load and immunologic responses against hiv

Conditions: HIV

Summary: the purpose of this study is to determine whether an immunization schedule is beneficial to hiv-infected patients with cd4 recount over 500 cells/mm3 and undetectable viral load.

as hiv-infected patients are considered immunocompromised, it is generally recommended that they have to receipt appropriate vaccines. however data are conflicting concerning potential harmful effects following the administration of commercial vaccines in hiv-infected patients. transient increases ("blips") in the viral load have been described associated with a single dose of vaccine, with the potential risk of developing resistance to haart. on the other hand, there has been described that patients with blips can have an increase in hiv-specific immune responses, which may help to improve the viral control. comparison: we have performed a clinical trial to evaluate the effect of a vaccination program in successfully treated hiv-infected adults on haart compared to placebo.

Eligibility criteria:
inclusion criteria: * age \>18 years * asymptomatic hiv infection * cd4\>500/mm3 \>6 months prior to inclusion * cd4 nadir \>300/mm3 * being under haart \> 1 year prior to inclusion * viral load\ 6 months prior to inclusion * viral load previous to treatment \>5000 copies/ml * informed consent exclusion criteria: * pregnant women * basal creatinine \>2.5 mg/dl * allergy to either a vaccine or a ingredient of it * chronic hepatitis b * got/gpt \> 250 iu/l

Keywords: hiv viral load vaccines immunotherapy
clinical routine in thoracic outlet syndrome

Conditions: Thoracic Outlet Syndrome

Summary: transversal recording and analysis of investigations performed in patients referred for suspected thoracic outlet syndrome (tos)

patients will have recording on a database of all investigations that were eventually performed for the diagnosis or follow up of their disease, among which: * characteristics (age, gender height, weight, ongoing treatment , * professional activity, sports activity, * symptoms. * forearm and finger photoplethysmography (ppg) during provocative maneuvers of the upper limb * transcutaneous oxymetry (tcpo2) recording * standard questionnaires (masc, dash, fs36) * doppler and ultrasound during provocative maneuvers of the upper limb * angiography during provocative maneuvers of the upper limb * electromyogram * standard x-ray

Eligibility criteria:
inclusion criteria: * absence of deny for the use of medical filesfor research purposes exclusion criteria: * inability to understand the purpose of the database. * patient protected by law.
anastrozole biphosphonate study in postmenopausal women with hormone-receptor-positive early breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to evaluate safety parameters of anastrozole with regard to its potential effects on postmenopausal bone loss and on lipid profiles. this trial is conducted to investigate the effects of risedronate on bmd and on bone metabolism in postmenopausal women using anastrozole as adjuvant therapy for hormone-receptor-positive early breast cancer and who are high or moderate risk of fragility fracture. it is also conducted to determine the effects of anastrozole on bone mineral density (bmd) and on bone metabolism in women at low risk of fragility fracture.


Eligibility criteria:
inclusion criteria: * women defined as postmenopausal * histologically proven operable invasive breast cancer * hormone-receptor-positive breast cancer exclusion criteria: * clinical evidence of metastatic disease * bilateral hip fractures or bilateral hip prosthesis * receiving or received in last 12 months hormonal therapy for breast cancer, bisphosphonate therapy, oestrogens * malabsorption syndrome

Keywords: hormone-receptor positive, breast cancer osteopenia osteoporosis risk of fracture bone loss
masitinib in combination with riluzole for the treatment of patients suffering from amyotrophic lateral sclerosis (als)

Conditions: Amyotrophic Lateral Sclerosis (ALS)

Summary: the objective is to compare the efficacy and safety of masitinib in combination with riluzole in the treatment of patients suffering from amyotrophic lateral sclerosis (als).

masitinib is novel tyrosine kinase inhibitor that targets microglia and mast cells through inhibiting a limited number of kinases. masitinib blocks microglia proliferation and activation, and mast cell-mediated degranulation, the release of cytotoxic substances that might further damage the motor nerves. there are two distinct populations of als patients: population of "normal progressors" and population of "faster progressors". targeted population for primary analysis is population of "normal progressors". "normal progressors" are als patients whose progression of alsfrs-r score before randomization is less than 1.1 point per month.

Eligibility criteria:
inclusion criteria: main inclusion criteria: 1. familial or sporadic als 2. patient diagnosed with probable of definite als 3. patient treated with a stable dose of riluzole (100 mg/day) for at least 30 days prior to screening exclusion criteria: 1. patient who underwent tracheostomy and/or gastrostomy

Keywords: amyotrophic lateral sclerosis (als) - masitinib
intermittent cold blood vs crystalloid cardioplegia in aortic valve surgery

Conditions: Aortic Valve Disease; Coronary Artery Disease

Summary: controversies still exists concerning the overall clinical effects of blood-based vs. crystalloid- based cardioplegic solution for myocardial protection during cardiac arrest. both techniques are used world-wide. no larger prospectively randomized studies comparing the two methods have been reported. the aim of this study is to collect a large number of clinical data to create a proper basis for evaluation of the two techniques.

all patients admitted for aortic valve replacement with or without concomitant cabg and operated by e.ø. or g.t. are included in the study. all preoperative, operative and postoperative data are prospectively recorded, focusing on clinical outcome parameters

Eligibility criteria:
aortic valve replacement
a feasibility study looking at the use of glibenclamide and metformin versus standard care in gestational diabetes

Conditions: Pregnancy; Gestational Diabetes

Summary: the aim of this open label feasibility study is to determine recruitment rates to a randomised trial of glibenclamide compared with insulin (both in addition to maximum tolerated metformin) for the treatment of gestational diabetes mellitus (gdm). this feasibility trial will inform the design of a future substantive multicentre trial to test the hypothesis that combination therapy with glibenclamide and metformin could reduce the number of pregnant women with gdm who require insulin and would be superior to metformin and insulin in terms of acceptability and cost effectiveness. women with gdm who have "failed" monotherapy with metformin will be recruited and randomised to either receive glibenclamide (test arm) or standard care with insulin, both in addition to their maximum tolerated dose of metformin. patients will be recruited from three of the antenatal clinics. this is a feasibility study in preparation for a large multicentre randomised trial to test the hypothesis that the addition of glibenclamide to metformin (combination therapy) could reduce the number of pregnant women with gestational diabetes mellitus requiring insulin, without compromising glycaemic control or other clinical outcomes. the investigators hypothesise that combination therapy with metformin and glibenclamide is likely to be preferable to metformin and insulin in terms of acceptability and cost.


Eligibility criteria:
inclusion criteria: * pregnant women diagnosed with gestational diabetes who fail to achieve "adequate glycaemic control" on maximum tolerated dose metformin * inadequate glycaemic control is defined according to the sign 116 guidelines. exclusion criteria: * pregnant women requiring insulin prior to 20 weeks gestation or after 36 weeks gestation. * pregnant women not taking at least 500mg metformin daily. * patients with suspected type 1 diabetes mellitus presenting in pregnancy. * women with allergies to either glibenclamide or insulin or any of their excipients. * women with any contraindications to sulfonylurea therapy. * women unable to give informed consent.

Keywords: pregnancy gestational diabetes glycaemic control metformin
role of health education in the semipresential logopedic treatment of the patient with oropharyngeal dysphagia

Conditions: Dysphagia

Summary: when reviewing the literature, the need to investigate the health education of patients with dysphagia and their family members / caregivers has been detected. numerous articles mention or it can be inferred from them that an education or training has been carried out for the patient and caregivers, but the investigators have not found any that specifically focuses on this aspect of the intervention. only in some clinical practice guidelines is the need for health education included


Eligibility criteria:
inclusion criteria: * people between 18 and 99 years old diagnosed by videofluoroscopy of oropharyngeal dysphagia and who are candidates for speech therapy treatment for this reason. * knowledge of the language sufficient to understand the audiovisual material on health education available at: logopediasantpau.wordpress.com * have the necessary technological tools to carry out the telematic processing (electronic device with internet access and whatsapp) and know how to use them or have a family member / direct caregiver with basic technological skills. * signature of the informed consent exclusion criteria: * moderate or severe cognitive impairment already known from the medical history or evaluated with the moca test in the absence of a family member or caregiver. * having undergone speech therapy treatment for oropharyngeal dysphagia in the last year. * not signing the informed consent.
restless legs syndrome with iron deficiency or anaemia in the 3rd trimester of pregnancy

Conditions: Restless Leg Syndrome; Iron Deficiency Anemia

Summary: in pregnancy restless legs syndrome(rls) is more common than in the general population. during pregnancy iron tablets are the only available safe medication but their efficacy is rather poor. it is the aim of this study to examine the efficacy, practicability and safety of the drug ferinject® containing the active agent ferric carboxymaltose for the therapy of restless legs syndrome(rls) during pregnancy in the case of iron deficiency or anaemia. 20 women with rls and iron deficiency and/ or anaemia in the third trimester of pregnancy will receive intravenous ferric carboxymaltose in one or two single doses. repeated blood tests, pre-and post-therapy actigraphy as well as repeated answering of questionnaires concerning restless legs syndrome(rls)-symptoms and sleep quality will show the effect of iv-iron supplementation on restless legs syndrome(rls)-symptoms during pregnancy. * trial with medicinal product


Eligibility criteria:
inclusion criteria: 1. pregnant women, singleton pregnancy, in the 3rd trimester 2. iron deficiency (anaemia) defined as serum ferritin \< 35ug/l with or without hb \< 11g/dl. 3. fulfilling the 4 criteria of the international restless legs study group (irlss) * uncomfortable and unpleasant sensations in the legs * an urge to move the legs due to this discomfort and worsening of the symptoms when resting * the unpleasant sensations are being relieved by movement such as walking or stretching * worsening of the symptoms in the evening or night 4. rls score \> 20 (defined as modest to severe rls symptoms) or rls symptoms = 3 times per week 5. patients = 18 years 6. signed informed consent provided exclusion criteria: criteria 1. age \< 18 years 2. multiple pregnancy 3. depression, psychiatric disease 4. severe internal underlying disease, that causes fatigue and sleepiness and thus may confound the outcome measures 5. abuse of alcohol, coffee or drugs 6. medication (antipsychotics, antihistaminics, tricyclic or ssri/snri antidepressants, l-dopa, antidopaminergic medication, medium to strong opioids, antiepileptic medication). 7. rls not due to iron deficiency: rls secondary to other central nervous system disease or injury. such disorders included peripheral neuropathy, neurodegenerative disorders and multiple sclerosis 8. rls secondary to chronic kidney disease 9. relevant chronic pain syndrome of the extremities other than rls 10. known proneness to allergic reactions 11. known hypersensitivity to ferric carboxymaltose 12. relevant disorders of iron metabolism of other aetiology than iron deficiency (e.g. hemochromatosis, hemosiderosis)

Keywords: rls pregnancy iron deficiency anaemia
effect of sensory training on activity limitation, functional use of hand and quality of life after wrist surgery

Conditions: Proprioception

Summary: the aim of this study is to determine the benefits of sensory training for participants who are included in rehabilitation after carpal tunnel surgery.


Eligibility criteria:
inclusion criteria: * sanko university health practice and research center, orthopedics and traumatology unit underwent open carpal tunnel loosening surgery. exclusion criteria: * the presence of nerve entrapment other than the median nerve (any sensory / motor deficits in the ulnar or radial nerve), * wrist injury history (fractures, carpal instabilities), * previous surgery in the hand or wrist region, * traumatic and recurrent carpal tunnel syndrome, inflammation of the tendon sheath or the presence of general active inflammation

Keywords: sensory carpal tunnel syndrome
intra-ureteric aminophylline instillation on flexible ureteroscopy procedure

Conditions: Stones, Kidney; Ureteric Injury

Summary: in this study we are going to evaluate the efficacy of intra-ureteric aminophylline instillation in facilitating ureteric access sheath placement prior to flexible ureteroscopy in reducing ureteric injury rates.

urolithiasis (kidney and ureteral stones) is a common urologic condition with increasing prevalence. flexible ureteroscopy (furs) is a minimally invasive technique widely used for upper ureteric and renal stones. aminophylline, a methylxanthine derivative, has been shown to relax smooth muscles and was previously used intravesically to facilitate rigid ureteroscopy with reduced complications. this study aims to assess whether intra-ureteric aminophylline instillation improves the ease of ureteral access sheath (uas) placement during furs and reduces ureteric injuries. patients will be divided into 3 groups: 1. group a (aminophylline group): intra-ureteric instillation of aminophylline 2. group b (ureteral dilator group): traditional ureteral dilators 3. group c (combination group): aminophylline instillation + ureteral dilators follow up of the patients will be through the success rate or failure of ureteric access sheath placement, operative time, bleeding, intra/postoperative complications and stone clearance (3-week follow-up with ct scan)

Eligibility criteria:
inclusion criteria: * upper ureteric stones or renal stones \< 2 cm exclusion criteria: 1. ureteric strictures. 2. anatomic renal disorders 3. functional renal disorders 4. urinary tract infection. 5. coagulopathy and uncorrected bleeding disorders. 6. prior dj stenting 7. any contraindication for aminophylline use: (hypersensitivity to theophylline, ethylenediamine, or any component of the drug formulation, pregnancy or lactation, active peptic ulcer, presence of cardiologic diseases, presence of neurologic diseases, presence of renal impairment and presence of hepatic dysfunction)

Keywords: aminophylline ureteric access sheath ureteric injury flexible uretroscopy
a clinical evaluation of a steroid-coated sinus stent when used following functional endoscopic sinus surgery in patients with chronic sinusitis

Conditions: Chronic Sinusitis

Summary: the purpose of this study is to assess the safety and efficacy of the propel mometasone furoate implant when used following functional endoscopic sinus surgery (fess) in patients with chronic sinusitis (cs).

the purpose of this study is to assess the safety and efficacy of the propel mometasone furoate implant when used following functional endoscopic sinus surgery (fess) in patients with chronic sinusitis (cs). the propel implant is designed to provide a mechanical spacing function within the sinus anatomy to separate mucosal tissues, provide stabilization of the middle turbinate, and thereby prevent tissue adhesions from forming. the implant is coated with a small amount of mometasone furoate (a corticosteroid) in order to help minimize post surgical inflammation within the supported tissues. the study utilizes an intra-patient control design to assess the safety and efficacy of the drug-coated implant compared to the non-drug coated implant that is identical in appearance.

Eligibility criteria:
inclusion criteria: * patient has bilateral chronic sinusitis confirmed by ct scan and defined as inflammation of the mucosa of the nose and paranasal sinuses of at least 8 consecutive weeks' duration. * patient is indicated for and has consented to fess. * fess successfully completed without significant complication that in the opinion of the physician would confound study results and the patient's anatomy remains amenable to sinus stent placement. ct imaging inclusion criteria: * cs diagnosis confirmed and documented by ct scan within 6 months of the procedure. * patient has minimum total ct score (lund-mackay method) of 6. • patient has bilateral ethmoid sinus disease confirmed by ct. exclusion criteria: * insulin dependent diabetics * oral steroid dependent condition * glaucoma, ocular hypertension, posterior subcapsular cataracts * middle turbinate resection
gene expression profiling of cervical cancer progression in biopsies and tissue samples

Conditions: Cervical Cancer; Precancerous Condition

Summary: rationale: studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this research trial is studying gene expression profiling of cervical cancer progression in biopsies and tissue samples from patients with cervical lesions.

objectives: * classify cervical cancer progression at a molecular level using gene expression profiling generated from expression microarrays. * profile gene expression changes of dysplasia and early carcinoma of uterine cervical tissue at a molecular level using expression microarrays. * define a set of genes that classify the various grades of cervical cancer/dysplasia at a molecular level. * compare the expression profiles of clinical data to determine how accurately cell lines model the in vivo environment. outline: patients undergo colposcopy and a cervical smear is taken for flow cytometry analysis. patients also undergo 2 biopsies from one clinically abnormal or normal site. tissue samples are analyzed by gene expression profiling using human expression microarrays containing approximately 40,000 unique sequences. data analysis consists of defining a set of genes, containing new targets for biomarkers, that classify the biopsies into 3 grades.

Eligibility criteria:
disease characteristics: * clinically suspicious malignant or premalignant cervical lesion criteria inclusion criteria: * included subjects will be ≥18 years old. * included subjects will not be pregnant. * included subjects will have a negative urine pregnancy test. * included subjects will be scheduled for colposcopy and/or leep treatment at the vgh women's clinic. * included subjects will indicate understanding of the study. * included subjects will provide informed consent to participate. exclusion criteria: * individuals \<18 years old will be excluded. * pregnant individuals will be excluded. * individuals that have had an operation to remove their cervix will be excluded.

Keywords: cervical cancer cervical intraepithelial neoplasia grade 1 cervical intraepithelial neoplasia grade 2 cervical intraepithelial neoplasia grade 3